In our upcoming “Science Simplified” series, we’ll be sharing insights from the latest research presented to us at the American Society of Hematology(ASH) conference . But before we explore that in detail, it is important to explain how we, and you, can read research critically.
In February 2026, the Follicular Lymphoma Foundation and the Josep Carreras Leukaemia Research Institute convened a global Scientific Conclave in Barcelona to confront the barriers slowing progress toward cures for follicular lymphoma. Over three days, leading experts aligned around clear priorities and a coordinated strategy designed to turn insight into decisive action for patients.
Every December, over 30,000 haematology experts from around the world gather for the American Society of Haematology (ASH) conference, where groundbreaking research is shared and the future of lymphoma treatment takes shape. In December 2025, the FLF team was at ASH in Orlando, USA on a clear mission: to find out the latest breakthroughs, represent you and drive progress toward a cure for follicular lymphoma.
In 2025 the FLF accelerated scientific momentum, strengthened global collaboration, and elevated the patient voice. In her first year as Global CEO, Emma France reflects on the turning points that pushed progress from possibility into action and shares how the FL community is shaping a future where cures become achievable.
The Follicular Lymphoma Foundation at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, one of the world’s premier gatherings for groundbreaking hematology research.
On November 18, 2025, the FDA approved epcoritamab-bysp (EPKINLY®) in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma after at least one prior therapy. This approval applies to patients in the United States..
The Unlock the Cure Gala 2025 brought supporters together to fund vital research and deliver hope for people living with follicular lymphoma.
At the recent 18th International Conference on Malignant Lymphoma (ICML), the FLF shone a spotlight on follicular lymphoma by hosting our very own satellite symposium for the second time, titled: “Charting our Progress Towards a Cure”. Read more to find out the key takeaways and highlights from the symposium.
In June 2025, the U.S. Food and Drug Administration (FDA) approved a new combination treatment option for adults with relapsed or refractory follicular lymphoma (FL).
This combination includes tafasitamab (also known as Monjuvi®, developed by Incyte), rituximab, and lenalidomide — and is now available for eligible patients in the United States.
One example of the impactful ways we advance our mission to cure follicular lymphoma (FL) is through our seed funding of the world-renowned Dana-Farber Cancer Institute.
We are thrilled to announce that the FLF will be taking centre stage at the upcoming 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, from June 17th-21st, 2025.
In recent weeks there have been a number of announcements regarding an alternative treatment option now being available for adults with relapsed/ refractory indolent follicular lymphoma (FL) across the EU and transformed follicular lymphoma within the UK.
The Mark Foundation for Cancer Research and the Follicular Lymphoma Foundation have joined forces to co-fund two new ASPIRE Awards focused on developing more personalized treatment strategies for FL.
The Follicular Lymphoma Foundation (FLF) was thrilled to participate in the recent American Society of Hematology (ASH) Annual Meeting.
The FLF welcomes Emma France as our new Global CEO. With over 20 years of non-profit leadership, Emma will help drive our mission forward with bold action and impactful change.
FLF’s CMO highlights key takeaways from ASH 2024 on follicular lymphoma, from immunotherapy to new treatments.
“Treat the person, not just the disease.”
World Cancer Day is on the 4th February. This year’s theme, United by Unique, emphasizes an essential shift in cancer care: putting patients at the heart of every decision.
This year has been transformative, marked by groundbreaking progress in our mission to cure follicular lymphoma.
We are thrilled to announce that our Unlock the Cure Gala Dinner saw us raise an astounding £800,000 to further our mission of finding a cure for follicular lymphoma.
Plain English Summary of the Publication:
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemo-immunotherapy.
Professor Jessica Okosun, FLF Scientific Advisor, answers your questions on chemotherapy-free options
Global patient survey results reveal key insights into patient perspectives on immunotherapy and information preferences
Our webinars are free, interactive, and designed to empower everyone affected by FL. Register today and stay informed on these important discussions.
We are pleased to announce the publication of our latest update, “Follicular Lymphoma: Mid-year Update on Pathways for Clinical and Translational Investigations.
Every 3 minutes, someone in the U.S. is diagnosed with blood cancer. Blood Cancer Awareness Month highlights leukemia, lymphoma, and myeloma.
Anne and Stewart recently completed an incredible 432-mile cycling journey in Scotland, raising over £2000 for the FLF.
View our webinar focused on sharing experiences and improving understanding of clinical trials.
Huge thanks to Tadmarton Heath Golf Club for hosting a charity event that raised over £6,000 for the FLF!
This strategic alliance with LLS and IFLI will further accelerate pioneering research and help cure follicular lymphoma through our Research United to CURE FL program.
The team updates from recent scientific conferences on the latest research in follicular lymphoma, from cutting-edge therapies to genetic insights.
Mark is going on an incredible 540 mile walk across the Pyrenees from the Atlantic to the Mediterranean.
Minimal/measurable residual disease refers to the small number of cancer cells remaining in the body after treatment.
How do we improve immunotherapy treatments to ensure long-lasting effectiveness, fewer side effects, and ensure they are accessible?
Dr Mitchell Smith, FLF CMO, explains Immunotherapy and what it means for people living with follicular lymphoma in terms of treatment.
Dr Mitchell Smith, FLF CMO, reports on the most exciting presentations at ASH 2023 including fundamental scientific discoveries and ongoing clinic trials.
Tali and Ross took on the incredible challenge of the Mongol Rally, a 10,000-mile dare devil adventure in a tiny 1000cc car.
We are thrilled to announce that this remarkable event saw us raise an astounding £500,000 to further our mission of finding a cure for follicular lymphoma.
The FLF will be attending the prestigious 65th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego this December.
Rosie took on the challenge of a half marathon alongside her husband and brother-in-law to raise funds for the FLF.
The panel addressed the crucial topic of “Accelerating the Impact of the Cancer Mission Five-Fold” moderated by IQVIA Institutes Executive Director.
Ben embarked on an epic 5-day, 550km cycling journey from London to Paris this past September.
Not many people are aware of Follicular Lymphoma, I wasn’t until my much better half Charlotte was diagnosed with the condition last year.
Our partnership with LLS continues with the second cycle of the “LLS-FLF United to CURE FL Awards”. This strategic alliance will further accelerate pioneering research and help cure follicular lymphoma.
Thank you to Kate for her incredible fundraising, including hosting a great pub quiz in June 2023. Kate’s advice to others who might be considering organising a fundraiser would be to “Just go for it!”.
The FLF joins forces with The Leukemia & Lymphoma Society to bring hope to those living with follicular lymphoma. The partnership marks a significant milestone in accelerating leading edge research.
This article presents key insights from the conference, shedding light on exciting developments in the field. The knowledge and insights we gained left us inspired and energised.
At the 17th International Conference on Malignant Lymphoma (17-ICML), the FLF hosted their own symposium: “What Will it Take to Cure FL?”. Read more to find out the key takeaways and highlights from the symposium.
In just the last six months, we have made tangible progress in advancing research, raising awareness, and working closely with patients.
Dr Mitchell Smith on Future Directions in FL Dr Mitchell Smith, CMO at the FLF, shares his insights in what the future holds for follicular
On May 18th, the FLF hosted our very first webinar called “An Overview of Follicular Lymphoma: What You Need to Know.”
Carolyn recently held a Coronation Afternoon Tea at her workplace to raise money for Follicular Lymphoma. FLF is a charity close to her heart due to
We’re thrilled to share a big step forward in our fight against follicular lymphoma. In April of this year, our founder, Nicola Mendelsohn, officially opened the new branch of the Follicular Lymphoma Foundation in Israel.
The Follicular Lymphoma Foundation (FLF) proudly hosted its first international FL Summit, titled “Joining Forces to Cure Follicular Lymphoma,” in Tel Aviv, Israel. The summit,
ASH Annual Meeting 2022 – summary and key take-outs By Dr Zoe Drymoussi During the 9-12th December 2022, the FLF team attended, in person, for
Looking back over the last 25 years for FL – the Rituximab era By Dr Mitchell Smith, Chief Medical Officer A recent re-publication marking 25
Research in focus: Bi-specific antibodies approval. By Dr. Zoe Drymoussi Over the last few years, a promising new class of treatments for advanced-stage FL has
New funding of $2 million for research to get one step closer to a cure for Follicular Lymphoma. Our mission at the FLF is to
Henry and Esther Shirman, two supporters that have been with the FLF since day one, recently celebrated their 50th wedding anniversary, and they certainly did
The wonderful Snowdown Colliery Welfare Brass Band recently (October 8th) created a fabulous afternoon of music for the local community of Dover, Kent. The band
Interesting summary of the impact and effectiveness of antibody responses to SARS- CoV-2 vaccines in patients with hematologic malignancies. A project from Michael J. Garil
For many people living with Follicular Lymphoma, periodic blood tests become a regular feature. There are several reasons you might need blood tests when affected
Any potential treatments for Follicular Lymphoma (and other forms of Non-Hodgkin lymphoma) must undergo extensive testing. They must be fully researched to confirm that they
The FLF places the patient at the heart of our organisation. This survey collated the unmet needs and prioritised our research goals.
